The literature and our above findings that OPN is expressed in various resident cells in the tumor microenvironment suggest that targeting serum OPN protein, rather than targeting a particular cell type, is potentially an effective approach to block OPN function in cancer patients, which provides a strong rationale to develop OPN neutralization monoclonal antibodies. The gene discussed is SPP1; the disease is cancer.